GlassScriptPhysician profile
Richard Eric Ej Madrid
NPI 1194774158
$5,678.66
in general payments reported to CMS, 2019-2025
35 companies · $998 in 2025
The $998 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $228 · 2021: $766 · 2022: $1,039 · 2023: $874 · 2024: $1,373 · 2025: $998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,244.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,071.76 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $493.25 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $490.05 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $437.22 | 2019-2025 | Freestyle Libre 3 |
| Abbvie INC. | $350.92 | 2021-2025 | |
| Amgen INC. | $291.86 | 2021-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.77 | 2019-2025 | Jardiance, Tradjenta |
| Pfizer INC. | $217.62 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $212.96 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $176.15 | 2019-2022 | |
| Lilly USA, LLC | $151.37 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Eisai INC. | $141.54 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $129.69 | 2022-2025 | |
| Antares Pharma, INC. | $117.25 | 2019-2023 | Nocdurna, Tlando, Xyosted |
| Intuitive Surgical, INC. | $105.24 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $98.26 | 2019 | |
| Merck Sharp & Dohme LLC | $96.52 | 2021-2023 | Gardasil 9, Vaxneuvance, Steglatro |
| Esperion Therapeutics, INC. | $95.22 | 2020-2024 | Nexletol |
| Currax Pharmaceuticals LLC | $93.22 | 2022-2025 | Contrave |
| Astellas Pharma US INC | $90.97 | 2024-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $82.06 | 2024-2025 | Rexulti |
| Dexcom, INC. | $66.80 | 2019-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $66.08 | 2022 | |
| Exact Sciences Corporation | $65.54 | 2024-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $52.76 | 2023-2025 | Gvoke Hypopen |
| Mannkind Corporation | $43.57 | 2021-2023 | Afrezza |
| Dynavax Technologies Corporation | $34.07 | 2023 | Heplisav-B |
| Lundbeck LLC | $30.83 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $22.53 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $22.07 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.16 | 2023 | Trintellix |
| Intra-Sana Laboratories | $16.35 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Verity Pharmaceuticals INC. | $15.53 | 2025 | Tlando |
| Allergan, INC. | $13.53 | 2019 | |
| Amarin Pharma, INC. | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Eric Madrid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.